Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics

The Journal of Urology
Firas AbdollahPierre I Karakiewicz

Abstract

The benefit of active treatment for prostate cancer is a subject of continuous debate. We assessed the relationship between treatment type (radical prostatectomy vs observation) and cancer specific mortality in a large, population based cohort. We examined the records of 44,694 patients treated with radical prostatectomy or observation between 1992 and 2005 in the SEER (Surveillance, Epidemiology and End Results)-Medicare linked database. Patients were matched by propensity score. Competing risks analysis was done to test the effect of treatment type on cancer specific mortality after accounting for other cause mortality. The number needed to treat was calculated. All analysis was stratified by prostate cancer risk group, baseline Charlson comorbidity index and patient age. For patients treated with radical prostatectomy vs observation the 10-year cancer specific mortality rate was 5.2% vs 12.8% for high risk prostate cancer, 1.4% vs 3.8% for low-intermediate risk prostate cancer, 2.4% vs 5.8% for a Charlson comorbidity index of 0, 2.3% vs 6.4% for a comorbidity index of 1, 2.5% vs 5.4% for a comorbidity index of 2 or greater, 2.0% vs 4.6% at ages 65 to 69, 2.6% vs 5.6% at ages 70 to 74 and 2.7% vs 8.1% at ages 75 to 80 years (...Continue Reading

References

Jan 9, 2001·Journal of Clinical Epidemiology·C N KlabundeJ L Warren
May 13, 2005·The New England Journal of Medicine·Anna Bill-AxelsonUNKNOWN Scandinavian Prostate Cancer Group Study No. 4
Sep 8, 2005·The Journal of Urology·Patrick C Walsh
Dec 14, 2006·JAMA : the Journal of the American Medical Association·Yu-Ning WongKatrina Armstrong
Jan 18, 2007·JAMA : the Journal of the American Medical Association·Ralph B D'Agostino, Ralph B D'Agostino
Apr 17, 2009·European Urology·Yu-Ning WongKatrina Armstrong
Sep 17, 2009·JAMA : the Journal of the American Medical Association·Grace L Lu-YaoSiu-Long Yao
Mar 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter C AlbertsenGrace L Lu-Yao

❮ Previous
Next ❯

Citations

Oct 12, 2012·Der Urologe. Ausg. A·C ThomasJ W Thüroff
May 14, 2014·Nature Reviews. Urology·Roderick C N van den Bergh, Gianluca Giannarini
Feb 19, 2016·CA: a Cancer Journal for Clinicians·Diana SarfatiChristopher Jackson
Sep 12, 2014·Cancer·Michael FroehnerManfred P Wirth
Jan 12, 2013·International Journal of Urology : Official Journal of the Japanese Urological Association·Joseph Ischia, Martin Gleave
Aug 22, 2014·International Journal of Urology : Official Journal of the Japanese Urological Association·Giorgio GandagliaMaxine Sun
Sep 16, 2018·Medical Oncology·Filippo PesapaneGeert Villeirs
Jul 28, 2013·Scandinavian Journal of Urology·Håkon WæhreHåvard E Danielsen
Dec 15, 2019·Medical Sciences : Open Access Journal·Travis P GreenRun Wang
Mar 18, 2017··M. O. VozdvizhenskiyV. A. Solovov

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.